Gene expression profiling in human endometrial cancer tissue samples: Utility and diagnostic value

Gynecologic Oncology

Volumn 93, Issue 2, 2004, Pages 292-300

  Smid Koopman, E ^a   Blok, L J ^a   Helmerhorst, Th J M ^a   Chadha Ajwani, S ^a   Burger, C W ^a   Brinkmann, A O ^a   Huikeshoven, F J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Endometrial cancer; Gene expression profile; Prognostic factors

Indexed keywords

COMPLEMENTARY DNA;

ADULT; AGED; ANALYTICAL PARAMETERS; ARTICLE; BENIGN TUMOR; CANCER DIAGNOSIS; CANCER TISSUE; CLUSTER ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC VALUE; ENDOMETRIUM; ENDOMETRIUM CARCINOMA; FEMALE; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; HUMAN TISSUE; MYOMETRIUM; PRIORITY JOURNAL; PROGNOSIS; SAMPLE; TUMOR CLASSIFICATION;

ADULT; AGED; AGED, 80 AND OVER; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; MULTIGENE FAMILY; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; SENSITIVITY AND SPECIFICITY;

EID: 1942541166     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2004.01.022     Document Type: Article

References (32)

1. Bristow R.E. Endometrial cancer. Curr. Opin. Oncol. 11:1999;388-393.
2. Central Office of Statistics of the Ministry of Public Health of The Netherlands, 1999.
3. Pecorelli S., Benedet J.L., Creasman W.T., Shepherd J.H. FIGO staging of gynecologic cancer. 1994-1997 FIGO Committee on Gynecologic Oncology. International Federation of Gynecology and Obstetrics. Int. J. Gynaecol. Obstet. 65:1999;5-10.
4. Abeler V.M., Kjorstad K.E. Endometrial adenocarcinoma in Norway. A study of a total population. Cancer. 67:1991;3093-3103.
5. Salvesen H.B., Iversen O.E., Akslen L.A. Prognostic impact of morphometric nuclear grade of endometrial carcinoma. Cancer. 83:1998;956-964.
6. Feltmate C.M., Duska L.R., Chang Y., Flynn C.E., Nikrui N., Kiggundu E.et al. Predictors of recurrence in surgical stage II endometrial adenocarcinoma. Gynecol. Oncol. 73:1999;407-411.
7. Evans M.P., Podratz K.C. Endometrial neoplasia: prognostic significance of ploidy status. Clin. Obstet. Gynecol. 39:1996;696-706.
8. Lim P., Aquino-Parsons C.F., Wong F., Dupuis B., Phillips D., Zhou C.et al. Low-risk endometrial carcinoma: assessment of a treatment policy based on tumor ploidy and identification of additional prognostic indicators. Gynecol. Oncol. 73:1999;191-195.
9. Creasman W.T. Prognostic significance of hormone receptors in endometrial cancer. Cancer. 71:1993;1467-1470.
10. Soong R., Knowles S., Williams K.E., Hammond I.G., Wysocki S.J., Iacopetta B.J. Overexpression of p53 protein is an independent prognostic indicator in human endometrial carcinoma. Br. J. Cancer. 74:1996;562-567.
11. Alizadeh A.A., Eisen M.B., Davis R.E., Ma C., Lossos I.S., Rosenwald A.et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 403:2000;503-511.
12. Alon U., Barkai N., Notterman D.A., Gish K., Ybarra S., Mack D.et al. Broad patterns of gene expression revealed by clustering analysis of tumor and normal colon tissues probed by oligonucleotide arrays. Proc. Natl. Acad. Sci. U. S. A. 96:1999;6745-6750.
13. Perou C.M., Sorlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees C.A.et al. Molecular portraits of human breast tumours. Nature. 406:2000;747-752.
14. Shim C., Zhang W., Rhee C.H., Lee J.H. Profiling of differentially expressed genes in human primary cervical cancer by complementary DNA expression array. Clin. Cancer Res. 4:1998;3045-3050.
15. Sorlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H.et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. U. S. A. 98:2001;10869-10874.
16. Mutter G.L., Baak J.P., Fitzgerald J.T., Gray R., Neuberg D., Kust G.A.et al. Global expression changes of constitutive and hormonally regulated genes during endometrial neoplastic transformation. Gynecol. Oncol. 83:2001;177-185.
17. Smid-Koopman E., Blok L.J., Chadha-Ajwani S., Helmerhorst T.J., Brinkmann A.O., Huikeshoven F.J. Gene expression profiles of human endometrial cancer samples using a cDNA-expression array technique: assessment of an analysis method. Br. J. Cancer. 83:2000;246-251.
18. Eisen M.B., Spellman P.T., Brown P.O., Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. U. S. A. 95:1998;14863-14868.
19. Perou C.M., Jeffrey S.S., van de Rijn M., Rees C.A., Eisen M.B., Ross D.T.et al. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc. Natl. Acad. Sci. U. S. A. 96:1999;9212-9217.
20. van't Veer L.J., Dai H., van de Vijver M.J., He Y.D., Hart A.A., Mao M.et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 415:2002;530-536.
21. Golub T.R., Slonim D.K., Tamayo P., Huard C., Gaasenbeek M., Mesirov J.P.et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 286:1999;531-537.
22. Clemens L.E., Siiteri P.K., Stites D.P. Mechanism of immunosuppression of progesterone on maternal lymphocyte activation during pregnancy. J. Immunol. 122:1979;1978-1985.
23. Siiteri P.K., Febres F., Clemens L.E., Chang R.J., Gondos B., Stites D. Progesterone and maintenance of pregnancy: is progesterone nature's immunosuppressant? Ann. N. Y. Acad. Sci. 286:1977;384-397.
24. Song J.Y., Fraser I.S. Effects of progestogens on human endometrium. Obstet. Gynecol. Surv. 50:1995;385-394.
25. Ehrlich C.E., Young P.C., Cleary R.E. Cytoplasmic progesterone and estradiol receptors in normal, hyperplastic, and carcinomatous endometria: therapeutic implications. Am. J. Obstet. Gynecol. 141:1981;539-546.
26. Bicsak T.A., Shimonaka M., Malkowski M., Ling N. Insulin-like growth factor-binding protein (IGF-BP) inhibition of granulosa cell function: effect on cyclic adenosine 3′,5′-monophosphate, deoxyribonucleic acid synthesis, and comparison with the effect of an IGF-I antibody. Endocrinology. 126:1990;2184-2189.
27. Baxter R.C. Signalling pathways involved in antiproliferative effects of IGFBP-3: a review. Mol. Pathol. 54:2001;145-148.
28. Butt A.J., Firth S.M., Baxter R.C. The IGF axis and programmed cell death. Immunol. Cell Biol. 77:1999;256-262.
29. Grimberg A., Cohen P. Growth hormone and prostate cancer: guilty by association? J. Endocrinol. Invest. 22:1999;64-73.
30. Shen L., Dean N.M., Glazer R.I. Induction of p53-dependent, insulin-like growth factor-binding protein-3-mediated apoptosis in glioblastoma multiforme cells by a protein kinase Calpha antisense oligonucleotide. Mol. Pharmacol. 55:1999;396-402.
31. Katsaros D., Yu H., Piccinno R., Puopolo M., Rigault De La Longrais I.A., Fracchioli S.et al. IGFBP-3. Expression and prognostic significance in epithelial ovarian cancer. Minerva Ginecol. 54:2002;15-24.
32. Lessey B.A., Albelda S., Buck C.A., Castelbaum A.J., Yeh I., Kohler M.et al. Distribution of integrin cell adhesion molecules in endometrial cancer. Am. J. Pathol. 146:1995;717-726.